Figure 1 (Oxaliplatin 01)
Oxaliplatin Injection, Solution, Concentrate
Product Images NDC 61703-363
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 61703-363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Oxaliplatin Structural Formula (Oxaliplatin 02)
This seems to be a table with some results displayed from a research study related to some treatments. The DPS Probability is shown as values for different time frames, and the table also shows some statistics related to the number of patients, events, ratios, and a Stratified Logrank Test. The bottom part of the table shows the number of patients at risk during different time frames. There is no information on what treatment is being evaluated, so further context is needed to understand the content of this table.*
Figure 2 (DFS Kaplan-Meier curves by treatment arm (cutoff: 1 June 2006))
This appears to be a table that shows DFS (disease-free survival) probability in months for two different treatment arms: FOLFOX4 and LVSFUZ, both under DUKES criteria. The table shows probability values ranging from 0.0 to 0.9 and the corresponding time frames in months. Additionally, the table displays the Stage I Hasard Ratio [95% CI) and Logrank Test results for the treatments.*
Figure 3 (DFS Kaplan-Meier curves by treatment arm in Stage III patients (cutoff: 1 June 2006))
This is a clinical study report presenting the median survival of patients with cancer under different drug treatments. The study compares the effectiveness of three drug combinations - ELOXATIN + 5-FUILV, ELOXATIN + irinotecan, and irinotecan + 5-FULV. The median survival of patients under each combination is presented as well as the percentage of surviving patients at different timepoints. The data suggest that Eloxatin plus 5-FUILV might be more effective than irinotecan plus 5-FUILV, based on the log-rank test.*
Figure 4 (Kaplan-Meier Overall Survival by treatment arm)
Hospira Logo (Oxaliplatin 06)
Principal Display Panel (10 mL Vial Label)
Principal Display Panel (10 mL Vial Carton)
This is a cautionary note for a product called "Oxaliplatin Injection". It contains 5mg of Oxaliplatin in each mL and is a cytotoxic agent. It also lists inactive ingredients like Tartaric Acid and Sodium Hydride. The package insert provides more details on the dosage and usage of the product. It is supposed to be stored at temperatures ranging from 20°C to 25°C and has to be discarded if not used. A single dose vial should not be mixed with sodium chloride/chloride-containing solutions. The product is distributed by Hospira, Inc.*
Principal Display Panel (20 mL Vial Label)
Principal Display Panel (20 mL Vial Carton)
The text contains information about the medication "Oxaliplatin", which is a sterile aqueous solution for intravenous use only. It is a cytotoxic agent that contains 5mg of Oxaliplatin per mL and should be stored at 20°-25°C (68°-T7°F) with excursions permitted to 15°-30°C (50°-86°F). The drug comes in a single-dose vial and caution is advised while handling the drug. The text includes the NDC code and the name of the distributor as Hospira, Inc. However, there is some unreadable text and gibberish present.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
